Abstract
Loss of norepinephrine (NE) releasing neurons, in the locus coeruleus of the brainstem, is well documented to occur in Alzheimers disease (AD). However, this process does not necessarily result in decreased release of NE, since compensatory mechanisms may produce increased release of this neurotransmitter. Independent of potential loss of locus coeruleus cells, brain NE levels may be elevated in some persons with AD, both before and during disease progression. Here I examine evidence that elevated, endogenous brain NE is an etiological factor in some cases of AD, and not merely an epiphenomenon of the disease. To explore this etiological hypothesis in AD, I examine the following eight lines of evidence: 1) direct evidence of elevated NE or its metabolites in AD; 2) studies of tricyclic antidepressants, which may principally boost NE; 3) studies of clonidine and other alpha2 adrenergic agonist drugs, which may principally lower the concentration of NE; 4) studies of beta adrenoceptor blocking drugs, including propranolol; 5) comorbidity of AD and bipolar disorder, where both disorders may involve elevated NE; 6) comorbidity of AD and hypertension; 7) comorbidity of AD and obesity; and 8) potential interaction between AD and psychological stress, where stressors are known to release NE. These lines of evidence tend to support the elevated NE etiological hypothesis.
Keywords: Dementia, tricyclic antidepressant, desipramine, clonidine, guanfacine, beta blocker, propranolol, bipolar disorder, hypertension, obesity, psychological stress
Current Alzheimer Research
Title: Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?
Volume: 7 Issue: 6
Author(s): P. J. Fitzgerald
Affiliation:
Keywords: Dementia, tricyclic antidepressant, desipramine, clonidine, guanfacine, beta blocker, propranolol, bipolar disorder, hypertension, obesity, psychological stress
Abstract: Loss of norepinephrine (NE) releasing neurons, in the locus coeruleus of the brainstem, is well documented to occur in Alzheimers disease (AD). However, this process does not necessarily result in decreased release of NE, since compensatory mechanisms may produce increased release of this neurotransmitter. Independent of potential loss of locus coeruleus cells, brain NE levels may be elevated in some persons with AD, both before and during disease progression. Here I examine evidence that elevated, endogenous brain NE is an etiological factor in some cases of AD, and not merely an epiphenomenon of the disease. To explore this etiological hypothesis in AD, I examine the following eight lines of evidence: 1) direct evidence of elevated NE or its metabolites in AD; 2) studies of tricyclic antidepressants, which may principally boost NE; 3) studies of clonidine and other alpha2 adrenergic agonist drugs, which may principally lower the concentration of NE; 4) studies of beta adrenoceptor blocking drugs, including propranolol; 5) comorbidity of AD and bipolar disorder, where both disorders may involve elevated NE; 6) comorbidity of AD and hypertension; 7) comorbidity of AD and obesity; and 8) potential interaction between AD and psychological stress, where stressors are known to release NE. These lines of evidence tend to support the elevated NE etiological hypothesis.
Export Options
About this article
Cite this article as:
J. Fitzgerald P., Is Elevated Norepinephrine an Etiological Factor in Some Cases of Alzheimers Disease?, Current Alzheimer Research 2010; 7 (6) . https://dx.doi.org/10.2174/156720510792231775
DOI https://dx.doi.org/10.2174/156720510792231775 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug-Induced Anemia and Other Red Cell Disorders: A Guide in the Age of Polypharmacy
Current Clinical Pharmacology Antioxidants in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders The Role of Exosomes and Exosome-derived microRNAs in Atherosclerosis
Current Pharmaceutical Design Subject Index To Volume 6
Current Molecular Medicine Dietary Fiber Gap and Host Gut Microbiota
Protein & Peptide Letters The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Editorial [Hot Topic (1): Update on Inflammatory Processes Governing Atherosclerotic Plaque Vulnerability and Reperfusion Injury (Guest Editors: Fabrizio Montecucco and Francois Mach)]
Current Pharmaceutical Biotechnology Effects of ADJUVANT Ketamine on Induction of Anesthesia for the Cesarean Section
Current Reviews in Clinical and Experimental Pharmacology Solvent Bar Microextraction Combined with HPLC-DAD for Simultaneous Determination of Diuretics in Human Urine and Plasma Samples
Current Pharmaceutical Biotechnology Brain Angiotensin II Involvement in Chronic Mental Disorders
Protein & Peptide Letters Development of a Triggered Nocturnal Blood Pressure Monitoring which Detects Nighttime Blood Pressure Surges in Sleep Apnea Syndrome
Current Hypertension Reviews Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Adverse Drug Reactions: Trends in a Tertiary Care Hospital
Current Drug Safety Anti-Inflammatory Effects of C-Peptide Prevent Endothelial Dysfunction in Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Anesthetic-induced Myocardial Conditioning: Molecular Fundamentals and Scope
Current Medicinal Chemistry Human Heart Failure: A Proteomics Perspective
Current Proteomics Mitochondrial genome sequencing in atherosclerosis: what's next?
Current Pharmaceutical Design Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry